



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/806,125

Filed: 3/28/2001

1st Inventor: E. Matsutani

For: Agent That Retards Transformation of
Hormone-Dependent Cancer to Non-
Hormone Dependent Cancer

Atty. Dkt. No. 2556 US0P

Art Unit: 1642

Examiner: Rawlings, S.

Allowed:

Batch:

Paper No.:

Response to Notice to Comply with Sequence Listing Requirements

MAIL STOP SEQUENCE

Commissioner for Patents

P.O. Box 1450

Arlington, VA 22313-1450

Sir:

In response to the Notice to Comply mailed October 7, 2004, Applicants respectfully submit, along with a copy of the Notice, a substitute paper copy of the Sequence Listing and a replacement DOS Text CRF Sequence Listing file "2556SEQ.txt" on the enclosed 3.5" IBM PC/AT computer disk.

I hereby state that the information recorded in the computer readable form is identical to the paper copy of the sequence listing. The Sequence Listing contains no new matter.

Respectfully submitted,

Dated: October 20, 2004

(847) 383-3391

(847) 383-3372

Elaine M Ramesh
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Mark Chao, Ph.D., Reg. No. 37,293
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA